Biosimilars Begin To 'Pay Off' For Biocon
Executive Summary
Biocon rang in a strong Q3, buoyed by the momentum in its biologics business. The firm appears undeterred by suggestions that the US biosimilars market may be less attractive than initially anticipated.
You may also be interested in...
Biocon Expects US Success For Biosimilar Trastuzumab Despite Amgen Launch
Leading Indian biologics firm Biocon reported first-quarter net profit soared more than 70% and said it is confident of a “very successful” US biosimilar trastuzumab launch, despite rival Amgen stealing a march by commercializing its own version first in the world’s largest drug market.
Biocon Biologics Reaches Landmark Sales Figure As IPO Beckons
Biocon rang in a strong fourth quarter amid signs of a build-up in efforts towards supporting the “independent functioning” of its biosimilars business under subsidiary Biocon Biologics.
Biocon Biologics Reaches Landmark Sales Figure; IPO Beckons
Biocon rang in a strong fourth quarter amid signs of a build-up in efforts towards supporting the “independent functioning” of its biosimilars business under subsidiary Biocon Biologics.